Substance / Medication

Mechlorethamine

Overview

Active Ingredient
mechlorethamine
RxNorm CUI
6674

Indications

VALCHLOR is indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.

Labeler: Helsinn Therapeutics (U.S.), Inc.Updated: 2024-11-20T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

The use of VALCHLOR is contraindicated in patients with known severe hypersensitivity to mechlorethamine. Hypersensitivity reactions, including anaphylaxis, have occurred with topical formulations of mechlorethamine.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

13 trials linked to this intervention

13
Total Trials
4
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Lack of Systemic Absorption of Topical Mechlorethamine Gel in Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma.
Querfeld Christiane, Geskin Larisa J, Kim Ellen J et al. · J Invest Dermatol · 2021
PMID: 33347924RCTFull text (PMC)
Mechlorethamine-based drug structures for intervention of central nervous system tumors.
Bartzatt Ronald · Cent Nerv Syst Agents Med Chem · 2013
PMID: 23745622Observational
Evaluation and management of patients with early-stage mycosis fungoides who interrupt or discontinue topical mechlorethamine gel because of dermatitis.
Gilmore Elaine S, Alexander-Savino Carolina V, Chung Catherine G et al. · JAAD Case Rep · 2020
PMID: 32904169Case ReportFull text (PMC)
Necrobiotic Xanthogranuloma Treated With Topical Nitrogen Mustard (Mechlorethamine).
Rodriguez Olaf, Meyers Charles, Weiss Brendan M et al. · JAMA Dermatol · 2016
PMID: 26762214Case Report
Optimizing Care and Compliance for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma With Mechlorethamine Gel.
Benjamin Chase Allister, Markel Kristen, Tawa Marianne C · Clin J Oncol Nurs · 2015
PMID: 26583648Case Report

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Chlormethine (substance)
SNOMED CT
372692002
UMLS CUI
C0025033
RxNorm CUI
6674
Labeler
Helsinn Therapeutics (U.S.), Inc.

Clinical Data

This intervention maps to 4 entities in the Healos knowledge graph.

4
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
13
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.